Prof Andrew Dick
Duke Elder Chair & Director of Institute Ophthalmology
Institute of Ophthalmology
Faculty of Brain Sciences
- Joined UCL
- 1st Sep 2015
My work on cytokines including TNF-alpha and the role of microglia in ocular inflammation (and retinal degeneration), has delivered new insights into the pathogenesis and new approaches to treatment of this group of important blinding diseases. I have been instrumental in taking these insights through to novel treatments. In the 90’s I lead the move of biologic therapy for uveitis forward in ophthalmology. Underpinned by experimental data, I first reported in a largest case series use of CAMPATH-1H via his collaboration with John Isaacs and Herman Waldmann for the successful treatment of refractory retinal vasculitis and ocular Wegener’s Granulomatosis (Brit J Ophthalmol 2000: 107-9; Brit J Ophthalmol 1999; 83: 1230). Furthermore my continued bench to bedside approach has been seminal in generating the evidence and scientific rationale that has led to the success of the use of anti-TNF agents in the treatment of non-infectious ocular inflammatory disease enjoyed in clinic today and has led to his many writings of reviews both science and clinical in this area (e.g. Prog Ret Eye Res 2004; 23: 617). With the science backdrop in my lab of basic macrophage biology and translational preclinical work (developed recently seminal paper for preclinical model outcomes utilizing Flow cytometry of single cell analysis alongside robust clinical outcomes non-invasively in animal models (IOVS , 2008: 49: 5458), I have generated evidence of macrophage plasticity during inflammatory and degenerative responses in the retina that has highlighted pathways for biologic therapeutic intervention such as agonist CD200R and C5aR inhibition to lead to early phase trials. In addition, we been one of only a very few groups that have generated via the expansive clinical experience and tertiary regional service in the NHS, evidence via our own RCTs (e.g Arch Ophthalmol 2005; 123: 634) in the use of standard immunosuppressive agents, quality of life (Brit J Ophthalmol 2005; 89: 1161) and ultimately improved care packages for patients.
Our work then set us to be engaged and incorporated and co-applicants of both the 2012 award for the £26.5M Experimental Biomedical Medicine platform of the NIHR-BRC at Moorfields and Institute of Ophthalmology, UCL and the successful UCL-Moorfields £5M Jules Thorn Infrastructural Application. We are now at an unparalleled time and have created consortium (NIH, USA and China) to build links to establish the operational infrastructure and large patient cohorts to deliver better understanding of mechanisms in man, undertake deep phenotyping, establish and test biomarkers, and a population for clinical trials.
- University of Aberdeen
- MD, Immunology | 1993
- University of London
- MBBS, Medicine | 1985
- University of London
- BSc Hons, Biochemistry | 1982
I qualified in medicine (MBBS) also with a degree in Biochemistry (BSc (Hons);2:1) from the University of London, and during my medical education I spent an MRC sponsored sabbatical as a research associate in Biochemistry with Professor Coleman in Yale. My medical education culminated with the Golding Medal and LLewellyn Scholarship for the top performance in the year at Medical School. I undertook MRCP training prior to entering ophthalmology residency and lecturership with Professor John Forrester in Aberdeen Scotland to further my science training. During this period I was awarded a prestigious MRC Post Doctoral Travelling Fellowship to work with Jon Sedgwick at the Centenary Institute of Cancer Medicine and Cell Biology in Sydney Australia and returned to take up Senior Lecturership at University of Aberdeen until my move to University of Bristol in 2000 as Chair and Professor of Ophthalmology.
My achievements include the award of Fellowship of Academy of Medical Sciences for exceptional contribution to the advancement of medical science and Alcon Research Institute Award in 2011 for outstanding contributions in the field of vision research. His work continues to be acknowledged internationally by invited and named lectures. Most recently the Transatlantic Visiting Professor at UCSF in 2005, Biennial Sir Duke Elder Lecture from Royal College of Ophthalmologists, UK in 2007, Frontiers in research Lecture, Bascom Palmer Eye Institute, USA 2008, NHG Overseas Expert, Singapore 2008, plenary lecture at RANZCO in 2009 and European Ophthalmic Research Lecture at EVER, in 2011. Overall he has written 2 text books, one with John Forrester and Colleagues - which still remains the best seller in the field (The Eye: Basic Science in Practice), the other being Practical Manual of Intraocular inflammation and over 15 chapter contributions and over 200 peer reviewed publications spanning basic to clinical science, with over 100 publications in the last 10 years. His extracurricular duties include: Past-Chair of IM section for ARVO, chair of uveitis working group for International Classification of disease with W.H.O., committee representation on European Immune-mediated inflammatory diseases workshop, steering committee member for global Standardised Uveitis Nomenclature working group, editorial board member of 5 international peer reviewed journals, including most recently Progress in Retinal and Eye Research. In the past I have been co-editor of British Journal of Ophthalmology with Professor Creig Hoyt. I contribute nationally (in UK) with his work with the Royal Colleges of Ophthalmologists and Royal College of Physicians, as well as Academy of Medical Sciences, committee of Medical Research Society and National Institute for Health Research, UK for the promotion of training, science and scholarship.